Differences in Clinical Outcomes Between Patients With Incidentally Detected and Clinically Detected Pheochromocytomas and Paragangliomas: A Retrospective Multicenter Study

dc.contributor.authorUzun, Ozden
dc.contributor.authorIcin, Buket Busra
dc.contributor.authorCakir, Bekir
dc.contributor.authorTural Balsak, Belma Ozlem
dc.contributor.authorNasiroglu Imga, Narin
dc.contributor.authorSoltanova, Lala
dc.contributor.authorZuhur, Sayid Shafi
dc.date.accessioned2026-09-08T07:13:15Z
dc.date.issued2026
dc.departmentFırat Üniveristesi
dc.description.abstractObjective With the increasing use of imaging, a substantial proportion of pheochromocytomas and paragangliomas (PPGLs) are detected incidentally. However, data comparing the clinical outcomes of patients with incidentally and clinically detected PPGLs remain limited. Therefore, we compared them in this study.Methods This multicenter retrospective study included 426 patients. Patients were classified as having incidentally or clinically detected PPGLs. Clinical, laboratory and genetic features; tumour stage; persistent/recurrent disease; disease-free survival (DFS); and overall survival were compared between patients with incidentally and clinically detected PPGLs.Results Among the patients, 216 had incidentally detected, and 210 had clinically detected PPGLs. Persistent/recurrent disease was diagnosed in 47 (11%) patients. Patients with incidentally detected PPGLs were older and more normotensive than those with clinically detected PPGLs. Hypertension, hereditary diseases, and persistent/recurrent diseases were more common in patients with clinically detected PPGLs. However, DFS did not differ between the two groups. Only hereditary disease and advanced tumour stage were associated with short DFS and were independent predictors of persistent/recurrent disease. Incidentally detected PPGLs were associated with low overall survival, a fact that could be confounded by the age.Conclusion The detection method was neither associated with short DFS nor a predictor of persistent/recurrent disease, whereas hereditary disease and tumour stage were associated with short DFS and were independent predictors of persistent/recurrent disease in patients with PPGLs. Therefore, genetic analysis, staging, and close follow-up are necessary to determine persistent/recurrent disease and develop individualised treatment and follow-up plans, irrespective of the detection method.
dc.identifier.doi10.1111/cen.70167
dc.identifier.endpage196
dc.identifier.issn0300-0664
dc.identifier.issn1365-2265
dc.identifier.issue2
dc.identifier.orcid0000-0002-1348-7706
dc.identifier.pmid42206758
dc.identifier.scopus2-s2.0-105040128718
dc.identifier.scopusqualityQ2
dc.identifier.startpage185
dc.identifier.urihttps://doi.org/10.1111/cen.70167
dc.identifier.urihttps://hdl.handle.net/11508/65383
dc.identifier.volume105
dc.identifier.wosWOS:001777094600001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofClinical Endocrinology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250903
dc.subjectAdrenal Gland Neoplasms
dc.subjectAdrenal Incidentaloma
dc.subjectCatecholamine
dc.subjectDisease-Free Survival
dc.subjectFollow-Up Studies
dc.subjectPheochromocytoma
dc.subjectRetrospective Studies
dc.titleDifferences in Clinical Outcomes Between Patients With Incidentally Detected and Clinically Detected Pheochromocytomas and Paragangliomas: A Retrospective Multicenter Study
dc.typeArticle

Dosyalar